CuraTeQ Biologics is an EU GMP-certified biopharmaceutical company with a pipeline of 14 biosimilars, including Bevqolva (bevacizumab, MHRA-approved), Zefylti (filgrastim) and Dyrupeg (pegfilgrastim, both EC- and MHRA-approved), and Dazublys (trastuzumab, EC-, MHRA- and CDSCO-approved). Its synthetic peptide API manufacturing arm, Auro Peptides, has filed 14 US DMFs contributing to 6 ANDA approvals, and the company also offers CMO services in biologics and peptides.

Aucun commentaire disponible.
Laissez votre note & commentaire